Searched for
GENERICIZATION
Raghuram Rajan's warning to India after Hormuz shock: Build bigger oil reserves, diversify fasterGlobal economic shocks from trade disruptions and geopolitical tensions are reshaping resilience, according to Raghuram Rajan. He stresses ...- Scientists just found that honey bees follow their own personal flight paths, and in a German farm landscape, some repeated the same route within centimeters because landmarks like trees seem to keep them locked on courseHoneybees exhibit human-like commuting habits, flying the same routes daily. Researchers observed bees maintaining precise flight paths, ev...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Why the ET Most Innovative AI Product Awards 2026 are spotlighting industry-specific innovationThe most impactful AI products of 2026 aren't built to do everything; they're built to solve one problem exceptionally well. The ET Most In...
- Winning with AI: Prompting a skill to thrillAI skills are changing how we work. Instead of generic claims, skills are now specific AI instructions. This allows users to train AI assis...
- Stocks in news: Dr Reddy’s, Adani Green, KIMS, JSW Energy, Nestle IndiaMarkets saw a strong rebound on Friday, driven by positive global cues and easing geopolitical tensions. Nifty defended the 23,000 support ...
- 12 years of Modi government strengthened India's health sector through accessibility and digital innovation: Amit ShahIndia's health sector has seen historic changes in the last 12 years. Accessible, affordable, and quality healthcare is now a reality for c...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- The future of AI may be a world where nobody talks about AIhe first wave of artificial intelligence was defined by models, capabilities, and technical breakthroughs. The next may be defined by somet...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- India's weight-loss market grows upThe landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...
- Career tips from a former recruiter: 8 things employers quietly notice on resumes that job seekers never hear aboutA Reddit post by a former recruiter and resume writer is drawing attention for revealing eight resume factors that hiring managers often lo...
- Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- India willing to open its market to high-quality, innovative pharma products, says commerce ministerIndia is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug ex...
- Carlyle-backed Viyash Scientific buys Italy’s BioForLife for Rs 188 croreViyash Scientific, backed by Carlyle, is acquiring Italy's BioForLife for Rs. 188 crore. This move aims to build a leading global companion...
- Pharma exports to US seen muted this yearIndian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...
Load More
